Login / Signup

Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.

Abdullah LadhaGavin HuiEdna CheungCaroline BerubeSteven E CoutreJason GotlibMichaela LiedtkeTian Yi ZhangLori MufflyGabriel N Mannis
Published in: Leukemia & lymphoma (2021)
Keyphrases
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • clinical practice
  • allogeneic hematopoietic stem cell transplantation
  • emergency department